Sign In
Buy KPTI
$9.00
-0.230 (-2.49%)
At Close: Jun 03, 2026
NEWTON, Mass., April 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Europea
NEWTON, Mass., April 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that health-rela
Revisiting Karyopharm Therapeutics
05:00pm, Friday, 09'th Apr 2021
Today, we revisit Karyopharm Therapeutics, a small oncology concern. The shares are off some 35% in 2021, despite the company continuing to execute well.
Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings
06:19am, Tuesday, 06'th Apr 2021
The National Medical Products Administration (NMPA) has approved Antengene Corporation Limited's Investigational New Drug Application for a Phase 1 trial of ATG-019 in China. The trial will evaluat
SHANGHAI and HONG KONG, April 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing a
Karyopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood Cancer
02:27pm, Monday, 29'th Mar 2021
The European Commission has granted conditional marketing authorization for Karyopharm Therapeutics Inc's (NASDAQ: KPTI) Nexpovio (selinexor) for multiple myeloma. The approval covers Nexpovio co
Karyopharm Stock: Rationale For Bullishness
08:00am, Friday, 12'th Mar 2021
Karyopharm Stock: Rationale For Bullishness
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA
07:00pm, Tuesday, 23'rd Feb 2021
SHANGHAI and HONG KONG, Feb. 23, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing an
Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q4 2020 Results - Earnings Call Transcript
03:08pm, Thursday, 11'th Feb 2021
Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q4 2020 Results - Earnings Call Transcript
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates
09:50am, Thursday, 11'th Feb 2021
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.72% and -0.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st
Karyopharm: Strong Potential, Low Price, Looks Investible
08:00am, Sunday, 07'th Feb 2021
KPTI is doing well with selinexor, with additional approvals and increasing sales. There are additional label expansions in the offing.
Reddit playing a major role in biotech trading action, says Jefferies top health care analyst
06:11pm, Thursday, 04'th Feb 2021
Jared Holz, Jefferies managing director and healthcare sector specialist, on which biotech stocks could be the next targets. With Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen
NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the European Medic
Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma
10:32am, Monday, 21'st Dec 2020
Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.
NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Foo
